Rezvilutamide for prostate cancer PSA rise after prostate surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 study tests rezvilutamide in men whose prostate-specific antigen (PSA) starts rising again after the prostate has been removed. It aims to see whether this treatment can help prevent or slow cancer spread after surgery, especially in men without signs of spread on scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man age 40 or older and were diagnosed with prostate adenocarcinoma (a prostate cancer type).
- After surgery, your PSA was very low (below 0.1 ng/mL) for at least 6 months, and now it has risen twice in a row with certain timing and level rules.
- Scans (bone scan plus CT/MRI) show no local return in the prostate area and no distant spread.
- Your cancer has not spread to lymph nodes on the surgical/pathology report (node-negative) or the nodes could not be assessed.
- Your general health is good enough (ECOG 0–1) and your heart pumping function is adequate (left heart ejection fraction at least 50%).
- You must meet basic blood/organ test limits and you can follow the study plan (either you will get salvage radiation, or you cannot or do not want radiation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new oral hormone blocker (rezvilutamide) to standard salvage radiation and hormone therapy can better control prostate cancer that has come back (rising PSA) after surgery.
This study tests whether taking a drug called apalutamide (combined with hormone therapy) after prostate removal helps prevent the cancer from returning. It is for men whose prostate cancer has a high risk of coming back after surgery.
This trial tests a precise type of radiation (called SBRT) to the prostate bed for men whose PSA starts rising after prostate removal surgery. It aims to see if this targeted approach can effectively treat the recurrence without needing long-term hormone therapy.
This trial tests the best way to treat prostate cancer that has come back after initial treatment (like surgery or radiation) and shows a few spots on a PSMA scan. It compares different salvage treatments, possibly including radiation and hormone therapy, to slow the cancer's growth.
This trial is for men with prostate cancer that has spread to other parts of the body and is being treated with hormone therapy. It looks at whether a drop in PSA levels after six months can help predict how well the treatment is working.
This trial tests if a daily pill called Rezvilutamide can prevent prostate cancer from returning in men who had their prostate removed and are at high risk of recurrence. It is for men who cannot or choose not to have radiation therapy.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.